Motoyuki Fukumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Motoyuki Fukumoto has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hidenaga Yamamori
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan
6 shared publications - Kazutaka Ohi
Department of Psychiatry Gifu University Graduate School of Medicine Gifu Japan
6 shared publications - Masatoshi Takeda
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan
6 shared publications - Ryota Hashimoto
Department of Pathology of Mental Diseases National Institute of Mental Health, National Center of Neurology and Psychiatry Kodaira Japan
6 shared publications - Yuka Yasuda
Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan
5 shared publications - Satomi Umeda-Yano
Department of Molecular Neuropsychiatry, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
3 shared publications
Latest Publications
- 1 April 2013
- Vol. 33 (2) , 67-9
Impact of the genome wide supported NRGN gene on anterior cingulate morphologyin schizophrenia.
- 1 April 2013
- Vol. 33 (2) , 67-9
Impact of the genome wide supported NRGN gene on anterior cingulate morphologyin schizophrenia.
- 1 January 2013
- Vol. 115 (12) , 1203-10
[How far have biomarkers in psychiatry advanced?].
A biomarker is defined as a biological indicator of normal or pathological processes, and a pharmacological response to a therapeutic intervention, whose characteristics can be measured and evaluated objectively. In medicine and health, biomarkers can be paraphrased as diagnostic methods objectively conducive to treatment. Here, we discuss biomarkers of schizophrenia as a representative mental illness, whose research has advanced compared with that of other disorders. Schizophrenia is a syndrome with a typical course and symptoms. Its pathophysiology and pathogenesis have not been elucidated (medically however, its underlying biological mechanisms are assumed to be present. That is, in biomarker discovery, when the pathogenesis and cause are elucidated, the patient group would not consiste of schizophrenia but, it is a new disease of "x x disease." For example, neurosyphilis is exogenous psychosis, by finding a biomarker of syphilis spirochete, a new disease concept of neurosyphilis could be distinguished from the schizophrenia). In this way, it can be said that biomarker research is essential for the development of new diagnostic and treatment methods for mental illness. There are several biomarker research methods such as genetic analysis, biological sample analysis, cognitive analysis, neurophysiology, neuroimaging, animal models, and post-mortem brain analysis. Further, studies have been made, however, biomarkers that can explain all of schizophrenia has not been found yet. As schizophrenia is assumed to be a heterogenous syndrome, it is believed that the etiology varies. Thus, there is a possibility that targeting schizophrenia as a whole will make it difficulty to find biomarkers for patients with schizophrenia. It is considered that appropriate subgroup analysis is needed. In order to overcome it, amount-of-resources strategy to find patients by using large of samples has been made mainly in Europe and the United States. In Japan, we have used sub-group analysis strategy to elaborate this issue such as the use of an intermediate phenotype. It is not possible to research a similar strategy, because of the limited funds and manpower in Japan compared to U. S. and Europe. As nationwide research organizations in Japan, such as IGC (Imaging genetics consortium), combination analysis of genetics and neuroimaging and COCORO (Cognitive genetics collaborative research organization), combination analysis of genetics and cognitive function, have been established, the development of biomarkers for mental illnesses is expected in the near future.
- 1 January 2013
- Vol. 115 (12) , 1203-10
[How far have biomarkers in psychiatry advanced?].
A biomarker is defined as a biological indicator of normal or pathological processes, and a pharmacological response to a therapeutic intervention, whose characteristics can be measured and evaluated objectively. In medicine and health, biomarkers can be paraphrased as diagnostic methods objectively conducive to treatment. Here, we discuss biomarkers of schizophrenia as a representative mental illness, whose research has advanced compared with that of other disorders. Schizophrenia is a syndrome with a typical course and symptoms. Its pathophysiology and pathogenesis have not been elucidated (medically however, its underlying biological mechanisms are assumed to be present. That is, in biomarker discovery, when the pathogenesis and cause are elucidated, the patient group would not consiste of schizophrenia but, it is a new disease of "x x disease." For example, neurosyphilis is exogenous psychosis, by finding a biomarker of syphilis spirochete, a new disease concept of neurosyphilis could be distinguished from the schizophrenia). In this way, it can be said that biomarker research is essential for the development of new diagnostic and treatment methods for mental illness. There are several biomarker research methods such as genetic analysis, biological sample analysis, cognitive analysis, neurophysiology, neuroimaging, animal models, and post-mortem brain analysis. Further, studies have been made, however, biomarkers that can explain all of schizophrenia has not been found yet. As schizophrenia is assumed to be a heterogenous syndrome, it is believed that the etiology varies. Thus, there is a possibility that targeting schizophrenia as a whole will make it difficulty to find biomarkers for patients with schizophrenia. It is considered that appropriate subgroup analysis is needed. In order to overcome it, amount-of-resources strategy to find patients by using large of samples has been made mainly in Europe and the United States. In Japan, we have used sub-group analysis strategy to elaborate this issue such as the use of an intermediate phenotype. It is not possible to research a similar strategy, because of the limited funds and manpower in Japan compared to U. S. and Europe. As nationwide research organizations in Japan, such as IGC (Imaging genetics consortium), combination analysis of genetics and neuroimaging and COCORO (Cognitive genetics collaborative research organization), combination analysis of genetics and cognitive function, have been established, the development of biomarkers for mental illnesses is expected in the near future.
- Open Access
- 26 May 2011
- Published by Springer Nature in Molecular Autism
- Vol. 2 (1) , 9
Gene expression analysis in lymphoblasts derived from patients with autism spectrum disorder
Background: The autism spectrum disorders (ASDs) are complex neurodevelopmental disorders that result in severe and pervasive impairment in the development of reciprocal social interaction and verbal and nonverbal communication skills. In addition, individuals with ASD have stereotypical behavior, interests and activities. Rare mutations of some genes, such as neuroligin (NLGN) 3/4, neurexin (NRXN) 1,SHANK3, MeCP2andNHE9, have been reported to be associated with ASD. In the present study, we investigated whether alterations in mRNA expression levels of these genes could be found in lymphoblastoid cell lines derived from patients with ASD.Methods: We measured mRNA expression levels ofNLGN3/4, NRXN1, SHANK3, MeCP2, NHE9andAKT1in lymphoblastoid cells from 35 patients with ASD and 35 healthy controls, as well as from 45 patients with schizophrenia and 45 healthy controls, using real-time quantitative reverse transcriptase polymerase chain reaction assays.Results: The mRNA expression levels ofNLGN3andSHANK3normalized byβ-actinorTBPwere significantly decreased in the individuals with ASD compared to controls, whereas no difference was found in the mRNA expression level ofMeCP2, NHE9orAKT1. However, normalizedNLGN3andSHANK3gene expression levels were not altered in patients with schizophrenia, and expression levels ofNLGN4andNRXN1mRNA were not quantitatively measurable in lymphoblastoid cells.Conclusions: Our results provide evidence that theNLGN3andSHANK3genes may be differentially expressed in lymphoblastoid cell lines from individuals with ASD compared to those from controls. These findings suggest the possibility that decreased mRNA expression levels of these genes might be involved in the pathophysiology of ASD in a substantial population of ASD patients.
- 26 May 2011
- Published by Springer Nature in Molecular Autism
- Vol. 2 (1) , 9
Open AccessGene expression analysis in lymphoblasts derived from patients with autism spectrum disorder
Background: The autism spectrum disorders (ASDs) are complex neurodevelopmental disorders that result in severe and pervasive impairment in the development of reciprocal social interaction and verbal and nonverbal communication skills. In addition, individuals with ASD have stereotypical behavior, interests and activities. Rare mutations of some genes, such as neuroligin (NLGN) 3/4, neurexin (NRXN) 1,SHANK3, MeCP2andNHE9, have been reported to be associated with ASD. In the present study, we investigated whether alterations in mRNA expression levels of these genes could be found in lymphoblastoid cell lines derived from patients with ASD.Methods: We measured mRNA expression levels ofNLGN3/4, NRXN1, SHANK3, MeCP2, NHE9andAKT1in lymphoblastoid cells from 35 patients with ASD and 35 healthy controls, as well as from 45 patients with schizophrenia and 45 healthy controls, using real-time quantitative reverse transcriptase polymerase chain reaction assays.Results: The mRNA expression levels ofNLGN3andSHANK3normalized byβ-actinorTBPwere significantly decreased in the individuals with ASD compared to controls, whereas no difference was found in the mRNA expression level ofMeCP2, NHE9orAKT1. However, normalizedNLGN3andSHANK3gene expression levels were not altered in patients with schizophrenia, and expression levels ofNLGN4andNRXN1mRNA were not quantitatively measurable in lymphoblastoid cells.Conclusions: Our results provide evidence that theNLGN3andSHANK3genes may be differentially expressed in lymphoblastoid cell lines from individuals with ASD compared to those from controls. These findings suggest the possibility that decreased mRNA expression levels of these genes might be involved in the pathophysiology of ASD in a substantial population of ASD patients.
- 1 January 2011
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 137 (2) , 79-82
Translational research for mental disorder —schizophrenia
- 1 January 2011
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 137 (2) , 79-82
Translational research for mental disorder —schizophrenia
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e314-e315
Two-channel near infrared spectroscopy activation curves of oxyhemoglobin during frontal tasks in schizophrenia
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e314-e315
Two-channel near infrared spectroscopy activation curves of oxyhemoglobin during frontal tasks in schizophrenia
- 1 June 2010
- Vol. 30 (3) , 103-7
[Risk genes for schizophrenia and neuronal plasticity: molecular target for antipsychotic discovery].
The dysbindin-1 gene (DTNBP1: dystrobrevin binding protein 1) has been identified as a susceptibility gene for schizophrenia. Genetic variations of DTNBP1 were reported to be associated with several intermediate phenotypes such as general cognitive ability, memory, and regional brain activation and cortical volume. In studies on postmortem brain tissue, decreased expression levels of dysbindin-1 were shown in patients with schizophrenia. Risk genetic variation of dysbindin for schizophrenia was associated with reduced expression of dysbindin in human brains. These data indicate that the dysbindin-1 gene may confer susceptibility to schizophrenia through reduced expression and that sandy mice lacking dysbindin-1 protein could be a unique animal model of schizophrenia. Sandy mice were less active, had heightened anxiety-like response, demonstrated deficits in social interaction and showed impaired long-term memory retention and working memory. Sandy mice demonstrated lower levels of dopamine, but not glutamate, in restricted brain regions. Several neuronal functions of dysbindin were reported, such as neurotransmitter release, direct interaction with presynaptic molecules, neuroprotection, cytosckeletal organization, and gene expression. To investigate dysbindin function in the brain could shed light on the etiology of schizophrenia and lead us to new hypotheses, novel diagnostic tools, and more effective therapies for the disorder.
- 1 June 2010
- Vol. 30 (3) , 103-7
[Risk genes for schizophrenia and neuronal plasticity: molecular target for antipsychotic discovery].
The dysbindin-1 gene (DTNBP1: dystrobrevin binding protein 1) has been identified as a susceptibility gene for schizophrenia. Genetic variations of DTNBP1 were reported to be associated with several intermediate phenotypes such as general cognitive ability, memory, and regional brain activation and cortical volume. In studies on postmortem brain tissue, decreased expression levels of dysbindin-1 were shown in patients with schizophrenia. Risk genetic variation of dysbindin for schizophrenia was associated with reduced expression of dysbindin in human brains. These data indicate that the dysbindin-1 gene may confer susceptibility to schizophrenia through reduced expression and that sandy mice lacking dysbindin-1 protein could be a unique animal model of schizophrenia. Sandy mice were less active, had heightened anxiety-like response, demonstrated deficits in social interaction and showed impaired long-term memory retention and working memory. Sandy mice demonstrated lower levels of dopamine, but not glutamate, in restricted brain regions. Several neuronal functions of dysbindin were reported, such as neurotransmitter release, direct interaction with presynaptic molecules, neuroprotection, cytosckeletal organization, and gene expression. To investigate dysbindin function in the brain could shed light on the etiology of schizophrenia and lead us to new hypotheses, novel diagnostic tools, and more effective therapies for the disorder.